Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ)
Nyingchi, CN
Tibet Cheezheng Tibetan Medicine Co., Ltd., along with its affiliated entities, specializes in the entire lifecycle of traditional Tibetan pharmaceuticals, from their research and development to manufacturing and distribution across China. The company's diverse range of drug products addresses various medical conditions, including those impacting the cardiovascular, respiratory, digestive, nervous, and musculoskeletal systems, as well as urinary, reproductive, and gynecological health. Established in 1995, the firm is headquartered in Nyingchi, China, and operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.04% | -3.88% | -7.68% | -14.47% | -14.81% | -11.03% | -13.30% | -18.09% | -20.98% | -13.69% | +12.87% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+3.3% ★ Q1'26: +0.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+8.2% Q1'26: +21.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+24.1% ★ Q1'26: -45.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+30.4% ★ Q1'26: +27.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+21.8% ★ Q1'26: +11.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.5% ★ Q1'26: +6.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.10× ★ Q1'26: 1.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2019 actual |
|---|---|---|---|
| Revenue |
1.26B
est.
|
1.21B
est: 1.40B (-13.1%)
|
1.40B
est: 1.40B (+0.4%)
|
| EBITDA |
346.74M
est.
|
373.48M
est: 384.89M (-3.0%)
|
442.26M
est: 384.89M (+14.9%)
|
| EBIT |
299.20M
est.
|
350.33M
est: 332.11M (+5.5%)
|
406.23M
est: 332.11M (+22.3%)
|
| Net Income |
—
est.
|
318.77M
|
364.25M
|
| SGA |
696.62M
est.
|
697.63M
est: 773.25M (-9.8%)
|
818.58M
est: 773.25M (+5.9%)
|
| EPS |
—
est.
|
0.60
|
0.69
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 16.9K | 0.40% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 77.1K | 0.39% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 3.9K | 0.44% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.6K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 19.4K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 955.7K | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 68.8K | 0.28% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 36.6K | 0.29% |
| 9 | Vanguard FTSE All-World UCITS ETF (USD) Accumulating VWRA.L | 0.00% | 241.2K | 0.19% |
| 10 | Vanguard FTSE All-World UCITS ETF (USD) Distributing VWRD.L | 0.00% | 241.2K | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ai Ping Zhang | Accounting Supervisor | — | — |
| Guilan Lu | Chief Financial Officer | — | female |
| Haijian Xia | President & Director | — | male |
| Jianqin Xiao | Executive Vice President | — | female |
| Jun Li | Senior Vice President | — | male |
| Min Zhao | Vice President | — | female |
| Ping Feng | Senior Vice President & Secretary of the Board of Directors | — | female |
| Tenzin Wanma | Director of Cultural Heritage | — | male |
| Tianzhe Li | Vice President | — | male |
| Weiwu Chen | Chief Scientific Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002287.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
